Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
biotech
5
×
boston blog main
boston top stories
cancer
5
×
eli lilly
5
×
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
novartis
5
×
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
cancer immunotherapy
pfizer
takeda pharmaceutical
abbvie
aduro biotech
alexion pharmaceuticals
biogen
What
bio
drug
roundup
approval
companies
latest
new
pharmaceutical
price
typically
acquisitions
address
alzheimer’s
approves
bails
biggest
biogen’s
biopharmaceutical
blueprint
brand
bridgebio
build
buy
cancer
capital
car
carries
ceo
certain
company’s
convo
daniel
debut
designed
develop
different
drugs
dyne’s
earlier
emerges
Language
unset
Current search:
biotech
×
novartis
×
photo
×
cancer
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More